Navigation Links
Nationwide 'GI Nurses & Associates Day' Celebrates Contributions of Gastroenterology and Endoscopy Professionals
Date:3/25/2009

Today's Local Winners Eligible for Consideration in National "Proud to Be GI" Award

CINCINNATI, March 25 /PRNewswire/ -- Today, the Society of Gastroenterology Nurses and Associates (SGNA), the premier society representing nursing professionals in gastroenterology and endoscopy, and Procter and Gamble Pharmaceuticals (P&GP), makers of the ulcerative colitis (UC) treatment Asacol(R) (mesalamine) delayed-release tablets, are proud to support "GI Nurses & Associates Day," a day marked to honor the achievements of certified gastroenterology (GI) and endoscopy professionals. In recognition of "GI Nurses & Associates Day," GI and endoscopy practices across the nation are identifying nurses and associates in their local offices to recognize these individuals for their dedication to patients and the larger GI community.

"The Asacol brand, on behalf of P&G Pharmaceuticals, proudly recognizes the crucial role GI and endoscopy nurses and associates play in patient care and the advancement of the GI field," said David Lacy, GI category director at P&G Pharmaceuticals. "We are pleased to draw the public's attention to these individuals, who are heroes to the patients that rely on their guidance and personal care. The Asacol brand's support of 'GI Nurses & Associates Day' is part of P&GP's ongoing commitment to serve healthcare providers and patients alike."

Top Nurses Compete For National Award

Today's local award recipients were selected by their peers for their ability to demonstrate leadership, professionalism, integrity, dedication to teamwork, effective communications skills and superior clinical skills. Local winners are also eligible to be nominated for SGNA's national "Proud to be GI" award, which will be announced at SGNA's 36th Annual Course in St. Louis, Mo. in May. Local GI offices can nominate local winners for the national award by completing the national award application found in the GI Nurses & Associates Day Kit. These kits can be obtained by GI professionals through SGNA Headquarters, by visiting www.sgna.org or through their local P&GP representative.

"As GI and endoscopy nurses and associates ourselves, we have a profound understanding of the diverse demands of our field and the passion with which we serve the needs of our patients," said Lisa Heard, BSN RN CGRN, president of SGNA. "We are excited that 'GI Nurses & Associates Day' gives the public and the GI/endoscopy fields a chance to recognize the outstanding commitment of these individuals, and we encourage all local units and facilities to submit their winners to SGNA for national consideration."

In addition to its well-known consumer brands, Procter & Gamble develops and markets a gastrointestinal platform that extends across pharmaceutical and over-the-counter brands. One of these brands is Asacol(R) (mesalamine) delayed-release tablets, available by prescription only, and currently celebrating more than 16 years as a trusted therapy. Asacol is indicated to treat mild to moderate UC, a form of inflammatory bowel disease, and to maintain remission of UC. Asacol is the number one most-dispensed oral mesalamine.(1) More information about Asacol can be found by visiting www.Asacol.com.

About the Society of Gastroenterology Nurses and Associates

The Society of Gastroenterology Nurses and Associates, Inc. (SGNA) is a professional organization of more than 8,500 nurses and associates dedicated to the safe and effective practice of gastroenterology and endoscopy nursing. SGNA carries out its mission by advancing the science and practice of gastroenterology and endoscopy nursing through education, research, advocacy and collaboration and by promoting the professional development of its members in an atmosphere of mutual support. For more information, visit www.sgna.org.

About Asacol(R) (mesalamine) Delayed-Release Tablets 400 mg

Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).

Asacol was well-tolerated in clinical studies. Overall, the incidence of adverse events with Asacol was comparable to placebo. In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35 percent vs. 36 percent), abdominal pain (18 percent vs. 14 percent), eructation (16 percent vs. 15 percent), pain (14 percent vs. eight percent) and nausea (13 percent vs. 15 percent); for the maintenance of remission of UC, the most frequent adverse events were headache (50 percent vs. 50 percent), rhinitis (42 percent vs. 36 percent), diarrhea (35 percent vs. 50 percent), abdominal pain (32 percent vs. 44 percent) and flatulence (24 percent vs. 30 percent). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol. Please visit http://www.asacol.com/pdf/us-asacol.pdf for full prescribing information.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Actonel(R), (risedronate sodium) tablets, Asacol(R) (mesalamine) delayed-release tablets, Enablex(R) (darifenacin) extended-release tablets, Prilosec OTC(R), Metamucil(R), Fibersure(R), Align(R), Pepto-Bismol(R), Vicks(R), PUR(R), Crest(R) and Oral-B(R). The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

(1) This information is an estimate derived from the use of information under license from IMS National Prescription Data for the 12 month period ending July 2008. IMS expressly reserves all rights, including rights of copying, distribution and republication. This statement does not imply superior efficacy or safety.


'/>"/>
SOURCE P&G Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, Americas Schools
2. Hagerstown Cosmetic Surgeon Weathers the Current Economic Storm Despite the Sharp Decline in the Number of Cosmetic Surgeries Performed Nationwide
3. The Center for Plastic Surgery in Washington, DC Survives the Economy Despite Nationwide Data Reported by ASAPS
4. Weaver Popcorn Company Issues a Nationwide Precautionary Voluntary Recall of 12 oz. (340g) Trails End(R) Chocolatey Peanut Clusters
5. Nationwide Medical/Surgical Announces Preservative Free Flu Vaccine Available
6. Wound Management Technologies Joins IMCO Vendor Network to Expand Sales Nationwide
7. ACIS Fitness Challenges Launch Across 200 Colleges Nationwide
8. Petfinder.com Foundation Rescues 500 Shelters and Rescue Groups Nationwide with $1 Million Worth of Generators
9. Thousands of Dentists Nationwide Mark First Annual Sedation Dentistry Safety Week
10. Compassionate Friends Bereavement Organization Recognizes 141 Compassionate Employers Nationwide
11. Nationwide Medical/Surgical Reveals Their Help Sheet For Those Infected with Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: